HiberCell: New Entrant to Fight Cancer Relapse and Metastasis

Commercialization of a Novel Approach to Saving Lives New York, New York-based HiberCell recently launched with the goal of...
Hideadenitis Suppurativa.

InflaRX Active in the Race for the Winning Hidradenitis Suppurativa Treatment

German and U.S. biotech venture InflaRX has been showcased before in one of our TrialSite News Hidradenitis Suppurativa (HS) articles. They recently...
Velocity Development

VELOCITY CLINICAL RESEARCH RAISES THE BAR FOR PATIENT RECRUITMENT

Dr. G. Paul Evans Named President and CEO Durham, N.C. -- February 5, 2019 – Velocity Clinical Research, a...
Hidradenitis Suppurativa and Cancer

Hidradenitis Suppurativa and Cancer: Is There a Connection?

Hidradenitis Suppurativa: A Horrible Disease Afflicting Millions Worldwide TrialSite News has been actively covering the serious skin disease and...

Massive Bio: Bringing World-Class Clinical Research to Patients and Patients to Clinical Research

Background Dr. Selin Kurnaz is on a mission to transform clinical research and ultimately improve healthcare outcomes. Blessed with...

Is XBiotech on the Cusp of a Superior Hidradenitis Suppurative Treatment?

TrialSite News has covered the hidradenitis suppurativa (HS) research pipeline. HS is a pervasive problem for so many. We are connected with hundreds...

Expansion Therapeutics: The Race to “Drug RNA”

Founded in 2016, Expansion Therapeutics (Expansion) is a drug discovery and development company pursuing the vast potential of small molecule medicines for...

The Emerging NASH Crisis

R&D Points Toward NASH In late 2018, Bay Area-based Gilead, known for HIV and Hepatitis C drugs, structured...
Stem Cell Research

Stem Cells Research: Promise and Possible Peril

Richard Poling was a 77-year-old from Indiana who suffered from pulmonary hypertension and pulmonary fibrosis.  His family sought out different options for...

Price Watch: The RESOLVE (PCYC-1137) Phase 3 Updates and IMBRUVICA

AbbVie updated markets via PR NewsWire on its RESOLVE (PCYC-1137) trial which evaluated ibrutinib in combination with chemotherapy agents nab-paclitaxel and gemcitabine...